Related Experiment Video

Updated: Jul 11, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Functional effects and molecular mechanisms of subtype-selective ERalpha and ERbeta agonists in the cardiovascular

P A Arias-Loza1, V Jazbutyte, K H Fritzemeier

  • 1Medizinische Klinik I, University of Würzburg, Josef-Schneider Str. 2, 97080 Würzburg, Germany.

Ernst Schering Foundation Symposium Proceedings
|September 11, 2007
PubMed

Insights

Estrogen receptor subtypes play a complex role in heart disease. Selective agonists targeting ERalpha and ERbeta show protective effects in animal models, offering potential new treatments for hypertension-related heart conditions.

Area of Science:

  • Cardiovascular Research
  • Endocrinology
  • Pharmacology

Background:

  • Gender disparities in cardiovascular disease (CVD) suggest a cardioprotective role for estrogens.
  • Hormone replacement therapy trials indicate a more complex function of estrogens in the cardiovascular system than previously understood.
  • Understanding estrogen's role requires detailed knowledge of estrogen receptor alpha (ERalpha) and estrogen receptor beta (ERbeta) functions in the heart and vasculature.

Purpose of the Study:

  • To review recent studies on subtype-selective estrogen receptor agonists.
  • To investigate the specific and redundant protective effects of ERalpha and ERbeta activation in cardiovascular conditions.
  • To explore potential novel therapeutic strategies for hypertensive heart disease.

Main Methods:

  • Review of recent scientific literature.
  • Analysis of studies utilizing subtype-selective ERalpha and ERbeta agonists.
  • Examination of data from animal models of hypertension, cardiac hypertrophy, and vascular inflammation.

Main Results:

  • Activation of specific estrogen receptor subtypes confers distinct protective effects in hypertensive heart disease.
  • Evidence suggests both specific and overlapping protective roles for ERalpha and ERbeta.
  • Subtype-selective agonists demonstrate potential in mitigating cardiovascular damage in preclinical models.

Conclusions:

  • The function of estrogens in cardiovascular health is complex and mediated by specific receptor subtypes.
  • Targeting ERalpha and ERbeta with selective agonists may offer novel therapeutic avenues.
  • Further research into subtype-selective estrogen receptor modulation holds promise for treating hypertensive heart disease.

Related Concept Videos

Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...